SpineX develops non-invasive spinal cord neuromodulation therapies designed to treat neurological conditions affecting motor and autonomic function. The company’s platforms, including SCONE™ and SCiP™, focus on modulating spinal neural circuits without surgical implantation. Its approach aims to restore functional signaling through targeted external stimulation. SpineX positions its technology within regulated clinical and rehabilitative care contexts.

The technology delivers patterned electrical stimulation to the spinal cord through the skin, targeting neural pathways involved in movement and autonomic control. By activating these circuits non-invasively, the system aims to enhance neural connectivity and functional output. Treatment protocols are designed to be repeatable and adaptable based on patient response. This approach emphasizes safety and accessibility compared to implantable spinal stimulation systems.

SpineX targets conditions such as neurogenic bladder, cerebral palsy, and other neurological impairments where spinal neuromodulation may improve function. The therapies are intended for use within clinical and rehabilitative settings under professional supervision. Its positioning reflects broader efforts to expand access to spinal neuromodulation through non-invasive, patient-friendly technologies.